Table 11.
Preventive measures of cognitive dysfunction in patients with AF | Class | Ref. |
---|---|---|
Appropriate anticoagulation in patients with AF and stroke risk factors should be applied for the prevention of cognitive dysfunction. | 107,111 | |
Consider NOAC instead of VKA when using oral anticoagulation for the prevention of stroke in AF, which may have a beneficial effect on subsequent cognitive disorders | 107,114 | |
In patients with AF managed with long-term VKA, a high anticoagulation time in therapeutic range may be beneficial for optimal prevention of new-onset dementia | 75,107 | |
General health measures (prevention of smoking, hypertension, obesity and diabetes, sleep apnoea, and appropriate control of all risk factors) may reduce the concomitant risks of AF (new onset or recurrences) and stroke, with a putative benefit on cognitive function. | 107,115 | |
Prevention of cognitive dysfunction in AF may include general measures proposed in vascular dementia or Alzheimer’s disease. | 116 | |
Cognitive assessment should be performed in AF patients where there is suspicion of cognitive impairment. | 204 |
AF, atrial fibrillation; NOAC, non-vitamin K antagonist oral anticoagulant; VKA, vitamin K antagonist.